Biosimilars Will Foster Competition and Lower Costs

Topic(s):

Legislation & Regulation , Managed Care Practice Issues , Biosimilars

The White House made news last month with its blueprint to lower drug prices. But it's also important to note that biosimilars will play a crucial role in fostering competition and lowering costs. Biosimilars are the topic of my latest op-ed, "How to Foster Competition While Cutting Drug Costs," published last month in Morning Consult. 

Related

AMCP AI 2
Blog

Why You Should Attend Nexus 2025

Each fall, thousands of managed care professionals gather for AMCP Nexus, a dynamic meeting you'll connect with the people, ideas, and innovations shaping the future of pharmacy and health care. Nexus 2025 is shaping up to be our most engaging and insightful gathering yet with new features, big names, and an even greater focus on connection, wellness, and professional growth.
AMCP Membership
AMCP AI 2
Blog

Takeaways from AI for Good Innovation Summit in Partnership with DC Tech & Venture Coalition (DCTAV)

Last week, over 450 health and technology leaders convened in a packed DC conference center for a morning summit on the present and future of Artificial Intelligence (AI) hosted by the DC Tech & Venture Coalition (DCTAV), a coalition of executives, entrepreneurs, and investors dedicated to improving the District of Columbia’s role as a hub of technology and capital.
Artificial Intelligence (AI)

Upcoming Events

Visit the AMCP Calendar

AMCP offers a wide variety of educational opportunities, from events and webinars to online training.

Annual Conference:

Learn More
Nexus 2025 logo


October 27-30 • • • National, Harbor